Literature DB >> 22082640

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.

J de Castro-Carpeño1, R Perona, C Belda-Iniesta.   

Abstract

The discovery of anaplastic lymphoma kinase (ALK) rearrangements in a subset of patients with nonsmall- cell lung cancer (NSCLC) and its potential blockage by specific inhibitors such as crizotinib has been one of the latest advances in the treatment of this disease. In this article, we will review the most important clinical aspects of ALK alterations in NSCLC patients and the pending questions to answer: the most effective means of diagnosing ALK-rearranged NSCLC, and efficacy, toxicity profile and potential mechanisms of resistance to crizotinib.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22082640     DOI： 10.1007/s12094-011-0732-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  28 in total

1.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Authors:  Young Lim Choi; Manabu Soda; Yoshihiro Yamashita; Toshihide Ueno; Junpei Takashima; Takahiro Nakajima; Yasushi Yatabe; Kengo Takeuchi; Toru Hamada; Hidenori Haruta; Yuichi Ishikawa; Hideki Kimura; Tetsuya Mitsudomi; Yoshiro Tanio; Hiroyuki Mano
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

Review 2.  New strategies for treatment of ALK-rearranged non-small cell lung cancers.

Authors:  Takaaki Sasaki; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2011-10-18       Impact factor: 12.531

3.  Cloning and localization of C2orf2(ropp120), a previously unknown WD repeat protein.

Authors:  H J Heidebrecht; F Buck; M Pollmann; R Siebert; R Parwaresch
Journal:  Genomics       Date:  2000-09-15       Impact factor: 5.736

4.  Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics.

Authors:  J Radtke; S G Rezaie; Ch Kugler; P Zabel; H Schultz; E Vollmer; T Goldmann; D S Lang
Journal:  Rom J Morphol Embryol       Date:  2010       Impact factor: 1.033

5.  Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.

Authors:  Christian C Lee; Yong Jia; Nanxin Li; Xiuying Sun; Kenneth Ng; Eileen Ambing; Mu-Yun Gao; Su Hua; Connie Chen; Sungjoon Kim; Pierre-Yves Michellys; Scott A Lesley; Jennifer L Harris; Glen Spraggon
Journal:  Biochem J       Date:  2010-09-15       Impact factor: 3.857

Review 6.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

7.  IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.

Authors:  Ping Shi; Raymond Lai; Quan Lin; Abid S Iqbal; Leah C Young; Larry W Kwak; Richard J Ford; Hesham M Amin
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

8.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

9.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

10.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Authors:  James G Christensen; Helen Y Zou; Maria E Arango; Qiuhua Li; Joseph H Lee; Scott R McDonnell; Shinji Yamazaki; Gordon R Alton; Barbara Mroczkowski; Gerrit Los
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261
View more
  1 in total

Review 1.  ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.

Authors:  Luis Cabezón-Gutiérrez; Parham Khosravi-Shahi; Victor Manuel Diaz-Muñoz-de-la-Espada; Jose Rafael Carrión-Galindo; Itziar Eraña-Tomás; María Castro-Otero
Journal:  Lung       Date:  2012-05-15       Impact factor: 2.584
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.